Ford John A, MacLennan Graeme S, Avenell Alison, Bolland Mark, Grey Andrew, Witham Miles
From the Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom (JAF, GSM, and AA); the Department of Medicine, University of Auckland, Auckland, New Zealand (MB and AG); and the Section of Aging and Health, University of Dundee, Dundee, United Kingdom (MW).
Am J Clin Nutr. 2014 Sep;100(3):746-55. doi: 10.3945/ajcn.113.082602. Epub 2014 Jul 23.
Low 25-hydroxyvitamin D status has been associated with increased cardiovascular events in epidemiologic studies.
We assessed whether vitamin D supplementation reduces cardiac failure, myocardial infarction (MI), and stroke through an analysis of the Randomised Evaluation of Calcium Or vitamin D (RECORD) randomized controlled trial (RCT), a systematic review, and a meta-analysis.
Two analyses were undertaken. The first analysis was a trial analysis. The RECORD was a factorial RCT that compared vitamin D₃ (800 IU/d), calcium (1000 mg/d), vitamin D plus calcium, and a placebo. Cardiovascular events were collected throughout the trial and 3-y posttrial follow-up. Data were analyzed by using Cox regression. The second analysis was a systematic review. MEDLINE, EMBASE, CENTRAL, conference abstracts, and ongoing trials were searched for RCTs that evaluated vitamin D from 1980 to 2013. RCTs with ≥1 y of follow-up and participants mean or median age ≥60 y were included. Meta-analyses were based on a Bayesian fixed-effects model by using a complementary log-log link function to account for varying lengths of follow-up.
In the trial analysis, we showed that, for the 5292 participants in the RECORD trial, HRs (95% CIs) for vitamin D compared with no vitamin D for cardiac failure, MI, and stroke were 0.75 (0.58, 0.97), 0.97 (0.75,1.26), and 1.06 (0.8, 1.32), respectively. Twenty-one studies met the inclusion criteria for the systematic review (n = 13,033). Estimated HRs (credible intervals) for vitamin D compared with the placebo or control for on-study events for cardiac failure, MI, and stroke were 0.82 (0.58, 1.15), 0.96 ( 0.83, 1.10), and 1.07 (0.91, 1.29), respectively.
Vitamin D supplementation might protect against cardiac failure in older people but does not appear to protect against MI or stroke.
在流行病学研究中,低水平的25-羟基维生素D状态与心血管事件增加有关。
我们通过对钙或维生素D随机评估(RECORD)随机对照试验(RCT)、系统评价和荟萃分析,评估补充维生素D是否能降低心力衰竭、心肌梗死(MI)和中风的发生风险。
进行了两项分析。第一项分析是试验分析。RECORD是一项析因随机对照试验,比较了维生素D₃(800 IU/天)、钙(1000 mg/天)、维生素D加钙和安慰剂。在整个试验期间及试验后3年随访中收集心血管事件。使用Cox回归分析数据。第二项分析是系统评价。检索MEDLINE、EMBASE、CENTRAL、会议摘要和正在进行的试验,以查找1980年至2013年评估维生素D的随机对照试验。纳入随访时间≥1年且参与者平均或中位年龄≥60岁的随机对照试验。荟萃分析基于贝叶斯固定效应模型,使用互补对数-对数链接函数来考虑不同的随访时间长度。
在试验分析中,我们发现,对于RECORD试验中的5292名参与者,与未补充维生素D相比,补充维生素D组发生心力衰竭、心肌梗死和中风的风险比(HRs)(95%可信区间)分别为0.75(0.58,0.97)、0.97(0.75,1.26)和1.06(0.8,1.32)。21项研究符合系统评价的纳入标准(n = 13,033)。与安慰剂或对照组相比,补充维生素D组在研究期间发生心力衰竭、心肌梗死和中风事件的估计风险比(可信区间)分别为0.82(0.58,1.15)、0.96(0.83,1.10)和1.07(0.91,1.29)。
补充维生素D可能对老年人预防心力衰竭有保护作用,但似乎对预防心肌梗死或中风无保护作用。